Q-omics provides the consensus-scored LOXL3 profile across patient tissues and cancer cell-line models. LOXL3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LOXL3 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LOXL3 protein abundance shows 19,535 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where LOXL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LOXL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LOXL3 survival associations across molecular data types. LOXL3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LOXL3 RNA expression–survival associations across cancer types. High LOXL3 expression shows unfavorable associations in KIRC, STAD, LGG and LIHC, but favorable associations in SCLC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LOXL3 RNA expression.
This table summarizes LOXL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LOXL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LOXL3 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, COAD, BRCA and CHOL. The HNSC box plot shows higher LOXL3 RNA expression in tumor versus normal tissue (log2 FC = +1.146, t-test p < 0.001).
This table shows molecular features associated with LOXL3 in patient tissues and cancer cell lines. In patient samples, LOXL3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LOXL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
